Member Info for Greenfish89

I dislike board changes it always makes me think something doddgy is going on. Has anyone found link to there old work so we can check what kind of success or failers are in their pasts.

or it's not naturally fractured the oil might not be mature enough, and its only water causing the flow rates ....like the last one.
ukog is not exactly gushing they are getting a sp[it of oil out of theit fault,
in my opinion

I bet we don't here anything till september, I bet they have not even started drilling. 12 years seems a long time

Will the drill results be good or bad ? yesterday last year they had an update it's like waiting for christmas

Stop talking rubbish he only said the summer until the last interview where he said hospital results should come out in July.

I peeped at the Faron Board they are worried about the trial stopping I guess they are waiting on news to se whats happeing.

so if we wanted to look for problems with Alex Borelli where migth we look?

now the whole*

I guess they would be one of our main competitors in a phase three trial. not the who thing about it reducing cytokine stormes makes me less happy

Is ifn B1a diffrent from our ifn b1? I read there rns saying they are upping production and the artical was all about how iv injections were much better than sc injections. I get how they are likely to to shout about inf b1 from the roof tops so it might not be 100% reliable. They got 2.1 million euros to bump up production from the EU

Severely ill COVID-19 patients with increased levels of plasma cytokines (especially IL-6) show signs of immune exhaustion and poor IFN responses [13]. Even in such cases, these patients would most likely benefit from IFN-beta, because it is the most potent anti-viral and anti-inflammatory agent of all interferons. It can induce the desired immune boost, but simultaneously downregulate IL-6 and IL-8 [14] and impair extravasation of neutrophils into lungs [15].
Conclusions

IFN-beta is now among the leading candidates to treat COVID-19 in various clinical trials, and i.v. and s.c. routes of administration are considered to be equal. This is not the case due to the different bioavailabilities of IFN-beta via i.v. and s.c. injections in target organs. This aspect needs to be taken seriously, when critically ill patients with compromised peripheral circulation are treated.
I like these end bits

summer

I support Thanos

I almost took the bate then :-)

Still no news on flow rates. So many people saying it's great it must be good .......
Dyor imo

Boom moon news coming soon :-) well July, August.

So where is this ggp help I put it in Google and all I get is gender gap help for gender reassignment. Unless it's just my Google ....

What worries me is they did not pick up the drug for asthma surely it showed it got rid of the virus. Why do t they snatch it up then and do this trial themselves if they had good virus reduction for asthma. You would think at that point it would be derisked enough.

Hopefully it works for all the copd patients and the results are great. The tissue sample must have given them a good foundation to work out what works.

Yes I'd say. Although saying that it depends what the cut of is for useful numbers helped. I'm not sure what effectiveness it has to get to.